Paper Details

  1. Home
  2. Paper Details

Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease.

Author: AllezM, ChangD J, D'HaensG, FeaganB G, FedorakR N, HeathA, JurgensenC H, LawranceI C, LeeS D, MaroneyA C, SandbornW J, SeidlerU, VermeireS

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Vercirnon did not demonstrate efficacy as an induction therapy in patients with moderately-to-severely active Crohn's disease.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Many patients with active Crohn's disease do not adequately respond to therapies, highlighting the need for new treatments. AIMS: To conduct a randomised, double-blind, placebo-controlled phase 3 study to assess the efficacy and safety of vercirnon, an oral inhibitor of CC chemokine rec...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/apt.13398

データ提供：米国国立医学図書館（NLM）

Vercirnon: A New Hope for Crohn's Disease?

The quest for effective treatments for Crohn's disease is a continuous journey, with many patients failing to respond adequately to current therapies. This research investigated the efficacy and safety of vercirnon, an oral inhibitor of CC chemokine receptor-9, as an induction therapy for patients with moderately to severely active Crohn's disease. The authors conducted a randomized, double-blind, placebo-controlled phase 3 study to evaluate vercirnon's effectiveness compared to placebo.

A Glimpse of Hope, Yet to Be Realized

The study results indicate that vercirnon did not demonstrate significant efficacy as an induction therapy for Crohn's disease. The proportions of patients achieving a clinical response were similar across all treatment groups, including placebo. While the research did not show efficacy for induction therapy, it did not address vercirnon's potential in maintenance therapy, leaving the door open for further exploration.

Navigating the Shifting Sands of Crohn's Treatment

This research highlights the ongoing search for effective treatments for Crohn's disease. While vercirnon did not demonstrate significant efficacy in this study, it's important to note that the research did not address its potential in maintenance therapy. This emphasizes the need for continued research and development of new treatment strategies for Crohn's disease. It's like navigating a vast desert - sometimes the path is clear, but sometimes you need to explore uncharted territory to find new solutions.

Dr. Camel's Conclusion

The quest for effective treatments for Crohn's disease continues. This research investigated the efficacy of vercirnon, an oral inhibitor of CC chemokine receptor-9, as an induction therapy, but it did not demonstrate significant efficacy. It's a reminder that the path to finding effective treatments for chronic conditions can be like navigating a vast desert - there may be unexpected turns and challenges, but we must continue our journey to find the best possible outcomes.

Date :
  1. Date Completed 2016-05-05
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

26400458

DOI: Digital Object Identifier

10.1111/apt.13398

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.